Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients

Annals of Hematology

Volumn 89, Issue 12, 2010, Pages 1233-1237

  Martínez Trillos, Alejandra ^a   Gaya, Anna ^a   Maffioli, Margherita ^a   Arellano Rodrigo, Eduardo ^a   Calvo, Xavier ^a   Díaz Beyá, Marina ^a   Cervantes, Francisco ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Hydroxyurea; Myelofibrosis; Primary myelofibrosis; Treatment

Indexed keywords

DANAZOL; ERYTHROPOIETIN; HYDROXYUREA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOCYTOSIS; MALE; MYELOFIBROSIS; PANCYTOPENIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; SPLENOMEGALY; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTISICKLING AGENTS; BONE AND BONES; FEMALE; HUMANS; HYDROXYUREA; LEG ULCER; LEUKOCYTOSIS; MALE; MIDDLE AGED; ORAL ULCER; PAIN; PANCYTOPENIA; PRIMARY MYELOFIBROSIS; PRURITUS; SPLENOMEGALY; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 78549245112     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1019-9     Document Type: Article

References (29)

1. RJ Jacobson A Salo PJ Fialkow 1978 Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis Blood 51 189 194 1:STN:280:DyaE1c%2FotFajuw%3D%3D 620081
2. G Barosi 1999 Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines J Clin Oncol 17 2954 2970 1:STN:280:DC%2BD3c%2FjtVWjtg%3D%3D 10561375
3. RA Mesa S Verstovsek F Cervantes, et al. 2007 Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Leuk Res 31 737 40 10.1016/j.leukres.2006.12.002 17210175 (Pubitemid 46855906)
4. R Kralowics F Passamonti AS Buser, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779 90 10.1056/NEJMoa051113 (Pubitemid 40570926)
5. AD Pardanani RL Levine T Lasho, et al. 2006 MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood 108 3472 76 1:CAS:528:DC%2BD28Xht1ahsLzI 10.1182/blood-2006-04-018879 16868251
6. F Cervantes 2005 Modern management of myelofibrosis Br J Haematol 128 583 592 10.1111/j.1365-2141.2004.05301.x 15725078 (Pubitemid 40343226)
7. P Guardiola JE Anderson G Bandini, et al. 1999 Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societé Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study Blood 93 2831 2838 1:CAS:528: DyaK1MXivVyltrc%3D 10216077
8. N Kröger E Holler G Kobbe, et al. 2009 Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Blood 114 5264 70 10.1182/blood-2009-07-234880 19812383
9. E Löfvenberg A Wahlin 1988 Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea Eur J Haematol 41 375 381 10.1111/j.1600-0609.1988.tb00212.x 3197824
10. A Manoharan 1991 Management of myelofibrosis with intermittent hydroxyurea Br J Haematol 77 252 254 1:STN:280:DyaK3M7mslaltQ%3D%3D 10.1111/j.1365-2141.1991.tb07989.x 2004030
11. FP Santos HM Kantarjian N Jain, et al. 2010 Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Blood 115 1131 36 1:CAS:528:DC%2BC3cXisFyrt7k%3D 10.1182/blood-2009-10-246363 20008298
12. A Pardanani H Hood T Lasho, et al. 2007 TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2 V617F and MPL W515L/K mutations Leukemia 21 1658 68 1:CAS:528:DC%2BD2sXnvVeltLo%3D 10.1038/sj.leu.2404750 17541402 (Pubitemid 47086756)
13. S Verstovsek HM Kantarjian AD Pardanani, et al. 2008 The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ET-MF) Blood 112 1762 abstract
14. A Tefferi J Thiele A Orazi, et al. 2007 Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel Blood 110 1092 1097 1:CAS:528: DC%2BD2sXptFKmurg%3D 10.1182/blood-2007-04-083501 17488875 (Pubitemid 47281402)
15. G Barosi D Bordessoule J Brière, et al. 2005 Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) Blood 106 2849 2853 1:CAS:528:DC%2BD2MXhtFantbbL 10.1182/blood-2005-04-1520 15994287 (Pubitemid 41510763)
16. A Tefferi G Barosi R Mesa, et al. 2006 International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, from the IWG for Myelofibrosis Research and Treatment (IWG-MRT) Blood 108 1497 503 1:CAS:528:DC%2BD28Xpt1Slt7s%3D 10.1182/blood-2006-03-009746 16675707 (Pubitemid 44316114)
17. F Cervantes A Alvarez-Larrán JC Hernández-Boluda, et al. 2004 Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature Br J Haematol 127 399 403 1:CAS:528:DC%2BD2cXhtVOms7jF 10.1111/j.1365-2141.2004.05229.x 15521916 (Pubitemid 39536591)
18. Alvarez-Larrán A Cervantes JC Hernández-Boluda, et al. 2006 Efficacy and safety of darbepoetin-alpha in the anaemia of myelofibrosis with myeloid metaplasia Br J Haematol 134 184 186 1:CAS:528:DC%2BD28Xot1ahtLo%3D 10.1111/j.1365-2141.2006.06142.x 16740139 (Pubitemid 43893910)
19. F Cervantes 2005 Alvarez Larrán A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients Br J Haematol 129 771 5 1:CAS:528:DC%2BD2MXms1ehsL8%3D 10.1111/j.1365-2141.2005.05524.x 15953003 (Pubitemid 40904527)
20. LH Brubaker J Brière J Laszlo, et al. 1982 Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only Arch Intern Med 142 1533 1537 1:STN:280:DyaL383lsFKksw%3D%3D 10.1001/archinte.142.8.1533 7103635 (Pubitemid 12048355)
21. RA Mesa DP Steensma A Pardanani, et al. 2003 A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia Blood 101 2534 2541 1:CAS:528: DC%2BD3sXivVWgur4%3D 10.1182/blood-2002-09-2928 12517815 (Pubitemid 36857609)
22. A Tefferi J Cortes S Verstovsek, et al. 2006 Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood 108 1158 64 1:CAS:528: DC%2BD28Xot1ymtL0%3D 10.1182/blood-2006-02-004572 16609064 (Pubitemid 44232010)
23. A Tefferi S Verstovsek G Barosi, et al. 2009 Pomalidomide is active in the treatment of anemia associated with myelofibrosis J Clin Oncol 27 4563 69 1:CAS:528:DC%2BD1MXhtlCns77E 10.1200/JCO.2008.21.7356 19652059
24. N Oishi SN Swisher SB Troup 1960 Busulfan therapy in myeloid metaplasia Blood 15 863 872 1:STN:280:DyaF3c7otFajsA%3D%3D 14428494
25. MC Petti R Latagliata T Spadea, et al. 2002 Melphalan treatment in patients with myelofibrosis with myeloid metaplasia Br J Haematol 116 576 581 1:CAS:528:DC%2BD38XislSns7s%3D 10.1046/j.0007-1048.2001.03331.x 11849213 (Pubitemid 34178656)
26. T Bachleitner-Hofmann H Gisslinger 1999 The role of interferon-α in the treatment of idiopathic myelofibrosis Ann Hematol 78 533 538 1:CAS:528:DyaK1MXotFertbo%3D 10.1007/s002770050554 10647876
27. A Tefferi RA Mesa DN Nagomey G Schroeder MN Silverstein 2000 Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients Blood 95 2226 2233 1:CAS:528:DC%2BD3cXitFeitr4%3D 10733489
28. MA Elliott MG Chen MN Silverstein A Tefferi 1998 Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia Br J Haematol 103 505 511 1:STN:280:DyaK1M%2FktlKhug%3D%3D 10.1046/j.1365-2141. 1998.00998.x 9827926 (Pubitemid 28522460)
29. E Löfvenberg A Wahlin G Roos A Öst 1990 Reversal of myelofibrosis by hydroxyurea Eur J Haematol 44 33 38 10.1111/j.1600-0609.1990. tb00344.x 2307218